Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia.
Zhou F, Aroua N, Liu Y, Rohde C, Cheng J, Wirth AK, Fijalkowska D, Göllner S, Lotze M, Yun H, Yu X, Pabst C, Sauer T, Oellerich T, Serve H, Röllig C, Bornhäuser M, Thiede C, Baldus C, Frye M, Raffel S, Krijgsveld J, Jeremias I, Beckmann R, Trumpp A, Müller-Tidow C. Zhou F, et al. Among authors: jeremias i. Cancer Discov. 2023 Feb 6;13(2):332-347. doi: 10.1158/2159-8290.CD-22-0210. Cancer Discov. 2023. PMID: 36259929 Free PMC article.
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I. Vick B, et al. Among authors: jeremias i. PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. eCollection 2015. PLoS One. 2015. PMID: 25793878 Free PMC article.
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C. Göllner S, et al. Among authors: jeremias i. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. Nat Med. 2017. PMID: 27941792 Free PMC article.
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS. Garz AK, et al. Among authors: jeremias i. Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312564 Free PMC article.
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
Garg S, Reyes-Palomares A, He L, Bergeron A, Lavallée VP, Lemieux S, Gendron P, Rohde C, Xia J, Jagdhane P, Müller-Tidow C, Lipka DB, Imren S, Humphries RK, Waskow C, Vick B, Jeremias I, Richard-Carpentier G, Hébert J, Sauvageau G, Zaugg JB, Barabé F, Pabst C. Garg S, et al. Among authors: jeremias i. Blood. 2019 Jul 18;134(3):263-276. doi: 10.1182/blood.2018862383. Epub 2019 May 10. Blood. 2019. PMID: 31076446 Free article.
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.
Lázaro-Navarro J, Pimentel-Gutiérrez HJ, Gauert A, Hagemann AIH, Eisenschmid J, Gökbuget N, Vick B, Jeremias I, Seyfried F, Meyer LH, Debatin KM, Richer K, Bultman M, Neumann M, Hänzelmann S, Serve H, Astrahantseff K, Rieger MA, Eckert C, Baldus CD, Bastian L. Lázaro-Navarro J, et al. Among authors: jeremias i. Blood Adv. 2021 Dec 28;5(24):5501-5506. doi: 10.1182/bloodadvances.2021004513. Blood Adv. 2021. PMID: 34610112 Free PMC article. No abstract available.
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, Göllner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre M, Gu M, Schlenk RF, Stölzel F, Bornhäuser M, Röllig C, Platzbecker U, Baldus C, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou G, Vick B, Jeremias I, Trumpp A, Krijgsveld J, Müller-Tidow C, Dietrich S. Janssen M, et al. Among authors: jeremias i. Blood. 2022 Dec 15;140(24):2594-2610. doi: 10.1182/blood.2021014241. Blood. 2022. PMID: 35857899 Free article.
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Thölken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, Münch C, Brandts CH. Koschade SE, et al. Among authors: jeremias i. Leukemia. 2022 Oct;36(10):2396-2407. doi: 10.1038/s41375-022-01678-y. Epub 2022 Aug 23. Leukemia. 2022. PMID: 35999260 Free PMC article.
145 results